|
KMID : 1149120220190010019
|
|
Journal of the Korean Society for Psoriasis
2022 Volume.19 No. 1 p.19 ~ p.22
|
|
|
Eczematous Skin Lesions after Risankizumab Treatment in a Patient with Psoriasis: A Case Report
|
|
Kang Jee-Woo
Jo Seong-Jin
|
|
|
Abstract
|
|
|
|
With the advancing knowledge on the pathogenesis of psoriasis, biologics targeting the interleukin-23 (IL-23)/T helper 17 (Th17) axis have become a safe and effective treatment for severe psoriasis. Recently, atopic dermatitis, often regarded as an immunological opposite of psoriasis, and similar eczematous lesions have been reported in psoriasis patients following treatment with IL-23 and IL-17 inhibitors. Eczematous lesions following biologics treatment in psoriasis patients are clinically important since discontinuation or switching of the offending biologics is necessary in some of the cases. Until now, eczematous lesions following treatment with tumor necrosis factor-α (TNF-α) and IL-17 inhibitors were reported in the majority of the cases, with relatively few reports regarding IL-23 inhibitors. Here we report a case of an eczematous eruption occurring nine months after treatment with risankizumab, leading to discontinuation of the biologics. The eczematous lesions resolved six months after discontinuation of risankizumab with no evidence of psoriasis recurrence.
|
|
|
KEYWORD
|
|
|
Eczema, Interleukin-23, Psoriasis, Risankizumab
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|